Within the phase 1–2 BRUIN basket study, 247 CLL patients previously treated with a covalent BTKI and a median of prior therapies of 3-40.5% had also been exposed to a BCL2 inhibitor, 18.2% to a PI3K inhibitor – were treated with pirtobrutinib at a standard dose of 200 mg once daily until disease progression or unacceptable toxicity. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.